Q1 Earnings Estimate for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Alector in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst A. Fein expects that the company will earn ($0.42) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Alector's current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Alector's Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.66) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.39) EPS.

Other analysts have also issued reports about the company. Cantor Fitzgerald restated an "overweight" rating on shares of Alector in a research note on Tuesday. Morgan Stanley downgraded shares of Alector from an "equal weight" rating to an "underweight" rating and dropped their target price for the stock from $10.00 to $3.00 in a research note on Tuesday. Finally, BTIG Research decreased their price target on shares of Alector from $16.00 to $5.00 and set a "buy" rating on the stock in a research note on Tuesday. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Alector currently has an average rating of "Moderate Buy" and a consensus price target of $14.00.

Alector Trading Down 1.0 %

ALEC stock traded down $0.02 during trading on Thursday, hitting $2.55. 2,866,555 shares of the stock traded hands, compared to its average volume of 679,041. The stock has a market cap of $249.24 million, a price-to-earnings ratio of -1.50 and a beta of 0.66. Alector has a one year low of $2.37 and a one year high of $8.90. The company has a 50 day simple moving average of $4.75 and a 200 day simple moving average of $5.02.

Alector (NASDAQ:ALEC - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.10. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The firm had revenue of $15.34 million during the quarter, compared to analyst estimates of $16.33 million.

Institutional Trading of Alector

Large investors have recently made changes to their positions in the company. Gladius Capital Management LP bought a new stake in shares of Alector in the second quarter worth about $29,000. Point72 DIFC Ltd acquired a new position in shares of Alector in the 3rd quarter valued at approximately $29,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Alector during the 3rd quarter worth approximately $40,000. nVerses Capital LLC acquired a new stake in Alector during the 3rd quarter worth approximately $51,000. Finally, Lazard Asset Management LLC acquired a new stake in Alector during the 1st quarter worth approximately $59,000. Institutional investors own 85.83% of the company's stock.

Insider Buying and Selling at Alector

In other Alector news, CEO Arnon Rosenthal sold 26,499 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now owns 1,948,746 shares of the company's stock, valued at approximately $9,509,880.48. This represents a 1.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Marc Grasso sold 7,297 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $35,609.36. Following the completion of the sale, the chief financial officer now owns 130,740 shares in the company, valued at approximately $638,011.20. This trade represents a 5.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,722 shares of company stock worth $232,883. Insiders own 9.10% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.